Organizations and agencies marked Rare Disease Day this week. Here are 5 things to know about rare disease.
Organizations and agencies marked Rare Disease Day this week. Most rare diseases do not have an approved treatment, according to the National Organization for Rare Disease (NORD). Here are 5 developments about rare disease.
1. Increased focus on outcome, measurement tools
There's been increased focus on the use of patient-reported outcomes and patient-reported outcome measures (PROMs), mostly in the oncology field. PROMs can help researchers understand how rare diseases and treatments impact quality of life and symptoms. Several health-related quality-of-life tools have been developed for rare diseases, including the phenylketonuria-specific quality-of-life questionnaire, several questionnaires related to birdshot chorioretinopathy, and the Fabry-specific pediatric health and pain questionnaire. However, for rare diseases, a number of challenges exist in using PROMs. For example, there are a limited number of PROMs validated for some target populations, especially for children and adolescents, and small samples sizes may lead to issues with sampling, data collection, and statistical analysis.
2. Tools reveal quality-of-life data
One observational study of patients with the myeloproliferative neoplasm polycythemia vera (PV) revealed the symptom burden associated with PV has a negative impact on quality of life, daily activities, and work productivity for many patients. The ongoing REVEAL study found that patients with PV experience symptoms and impairments that negatively affect their lives.
3. Payers are paying attention
Last year, Express Scripts announced a Rare Conditions Care Value program that includes the introduction of a support service known as Second Opinion, which offers guidance and expert case review for patients on an individual basis, with PinnacleCare. The service is aimed at addressing the challenges patients with rare diseases face through reducing the emotional, physical, and financial burden, including misdiagnosis and inappropriate treatments. However, a writer with the advocacy group Global Genes questioned the motivation of the pharmacy benefits manager, noting their customers are health insurance plans, and wondered whether or not the program was to help patients, or to control the rising cost of specialty drugs.
4. FDA adds additional patient perspective
As part of its acknowledgement of Rare Disease Day, the FDA said it is taking 2 actions to incorporate the voice of the patient into its programs. It will host a public meeting on April 29 called ”Patient Perspectives of the Impact of Rare Diseases: Bridging the Commonalities” in order to hear patients’ and caregivers’ perspectives on how rare diseases impact their daily lives. The FDA said it is trying to "assess commonalities to synergize product development in rare diseases." The FDA also announced it would be improving its grant review process by providing reviewers with patient perspectives.
5. Rare diseases are still being discovered
A recent paper from the New England Journal of Medicine discussed the work of the Undiagnosed Diseases Network, encompassing specialized teams working in 12 clinics across the country to diagnose people who do not have a name for their mysterious and severe conditions.1 So far, the team has uncovered 31 syndromes that were not previously known.
Reference
1. Splinter K, Adams DR, Bacino CA, et al. Effect of genetic diagnosis on patients with previously undiagnosed disease. N Engl J Med 2018; 379:2131-2139 doi: 10.1056/NEJMoa1714458.
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
November 21st 2023Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Odevixibat Safe for Alagille Syndrome Based on Hepatic Changes
November 8th 2023Pooled phase 3 data presented at North American Society for Pediatric Gastroenterology, Hepatology & Nutrition 2023 support the benefit-risk profile of the ileal bile acid transport inhibitor in treating the rare liver disease.
Read More
Contributor: How Patients and Caregivers Can Be a Catalyst for Rare Disease Innovation
November 5th 2023Patient input and experiences play a crucial role in advancing rare disease research and therapy development, as they help define the disease, inform clinical trial design, and influence regulators and payers' decisions, ultimately serving as catalysts for innovation in the field.
Read More